|
| Observation on curative effect of montelukast combined with winter disease cured in summer asthma ointment on chronic bronchial asthma |
| Hits 1396 Download times 1319 Received:April 12, 2018 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2018.09.09 |
| Key Words
bronchial asthma;montelukast;winter disease cured in summer;asthma plaster |
| Author Name | Affiliation | | JIN Wenman | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | DU Hongzhe | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China | | CHEN Hanjiang | Department of Pediatrics, The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China |
|
| Abstract
|
| [Objective] To evaluate the curative effect and safety of montelukast combined with winter disease cured in summer asthma ointment in the treatment of chronic bronchial asthma.[Methods] The 110 cases of patients with chronic bronchial asthma were randomly divided into the study group and the control group. Both of the two groups were treated with routine treatment. Based on this, the control group was treated with montelukast sodium tablets. The study group was additionally treated with winter disease cured in summer asthma ointment (Dog Day-Sanku plaster) based on the treatment in the control group, differentiation of syndromes to get the point, in the first, second and third dog day, the plasters were attached 2~3 h/time. The end of dog day each year was taken as 1 course of treatment. All of them received 1courses of treatment and were followed up for 1 year. The curative effect was compared between the two groups. The changes of forced vital capacity (FVC) and forced respiratory volume in 1 second (FEV1) in the two groups were measured by the pulmonary function instrument; changes of nuclear factor kappa B signaling pathway (NF-κB), interleukin-6 (IL-6) and interleukin-8 (IL-8) levels in the two group before and after treatment were measured by enzyme linked immunosorbent assay (ELISA); the improvement of asthma symptom score was recorded before and after treatment. Safety of treatment in the two groups was monitored and the recurrence rate was statistically analyzed.[Results] 1) The total effective rate in the study group (96.36%) was higher than that in the control group (80.00%, P<0.05); 2) Six months and 8 months after treatment, FVC and FEV1 in the two groups were higher than those before treatment. Those 12 months after treatment was higher than those 6 months after treatment and those in the study group were higher than those in the control group (P<0.05); 3) Six months and 8 months after treatment, NF-κB, IL-6 and IL-8 in the two groups were lower than those before treatment and those 12 months after treatment were lower than those 6 months after treatment. The decreasing range of indexes in the study group was greater than that in the control group (P<0.05); 4) There was recurrence in1 case (1.82%) in the control group and 9 cases (16.36%) in the control group during follow-up period (P<0.05).[Conclusions] To adopt montelukast combined with winter disease cured in summer asthma ointment in the treatment of chronic bronchial asthma can improve the lung function, reduce the levels of inflammatory factors and reduce the recurrence rate of asthma and it has high safety. |
|
|
|
|
|
|
|
